Hypertension

crps mental illness :: Article Creator Pikes Peak Rising: A New Mental Health Resource Hub For Community Members COLORADO SPRINGS, Colo. — Mayor Yemi Mobolade joined by his wife, Abbey Mobolade, and Colorado Springs City officials announced the name of a new regional initiative on mental health on Wednesday. Over 40 organizations have joined to help launch this initiative and will work together to boost awareness of mental health needs in the Pikes Peak region. The U.S. Surgeon General has identified an increasing mental health crisis in the United States. Pikes Peak Rise was created to help combat the crisis and build a stronger community in Colorado Springs. Inspired by their own connection to navigating mental health with family and friends, the Mobolades helped launch the initiative which is part of the City's 2024-2028 Strategic Plan. The Strategic Plan is focused on community activation and calls on the City of Colorado Springs to en...

cochrane collaboration blood pressure study :: Article Creator Method Enables Fast, Accurate Estimates Of Cardiovascular State To Inform Blood Pressure Management If patients receiving intensive care or undergoing major surgery develop excessively high or low blood pressures, they could suffer severe organ dysfunction. It's not enough for their care team to know that pressure is abnormal. To choose the correct drug to treat the problem, doctors must know why blood pressure has changed. A new MIT study presents the mathematical framework needed to derive that crucial information accurately and in real time. The mathematical approach, described in a recent study in IEEE Transactions on Biomedical Engineering, produces proportional estimates of the two critical factors underlying blood pressure changes: the heart's rate of blood output (cardiac output) and the arterial system's resistance to that blood flow (systemic vascular resistance). B...

glaucoma clinical trials 2021 :: Article Creator Nicox Announces Recruitment Of Last Patient In US In Denali Phase 3 Trial Of NCX 470 According to the company, the Denali trial is evaluating NCX 470 safety and efficacy in patients with open-angle glaucoma or ocular hypertension and topline results continue to be expected in H2 2025 (Image credit: Adobe Stock) Nicox SA announced the recruitment and randomization of the last patient in the U.S. In its Denali Phase 3 trial of NCX 470. The company noted that NCX 470 is a novel NO-donating bimatoprost eye drop currently in Phase 3 clinical development. According to a news release, the Denali trial is evaluating NCX 470 safety and efficacy in patients with open-angle glaucoma or ocular hypertension and topline results continue to be expected in H2 2025, based on this completion of recruitment of patients in the U.S. And continuing good progress of the trial in China, where recruitment of...

cdc clinical trials :: Article Creator Morning Rounds: Three New Bird Flu Cases In Humans Brings Total To 13 In U.S. Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in your inbox. I'm Brittany Trang, STAT health tech reporter and your new Friday morning host. One year ago today, several of us from STAT dressed up in pink and saw the Barbie movie together. I'm still thinking about the ambiguity of the movie's last line, and as you'll see below, medical researchers are too. Bird flu cases in humans now total 13 in U.S. The number of confirmed human infections with the bird flu virus associated with the ongoing outbreak in dairy cattle has risen to 13, the Centers for Disease Control and Prevention announced Thursday, as it confirmed three additional cases in Colorado. They are currently designated simply as H5 and not H5N1 because CDC labs are still working on typing the neuraminidase, the N numb...

a clinical trial :: Article Creator Hemophilia A Gene Therapy Superior To FVIII Replacement In Phase 3 Trial Giroctocogene fitelparvovec, an investigational gene therapy for adults with hemophilia A, is generally well tolerated and superior to standard replacement therapy in reducing bleeds, according to new top-line results from a Phase 3 clinical trial. The open-label trial, dubbed AFFINE (NCT04370054) and sponsored by Pfizer, has now treated 75 men with moderate to severe disease. It compared a patient's annualized bleeding rate in the months before the study's start — while on factor VIII (FVIII) prophylaxis, or preventive, replacement therapy — to that following at least 15 months after the one-time gene therapy infusion. The early results show the gene therapy worked better than FVIII treatment to reduce bleeds, Pfizer announced in a company press release. "I'm excited by the strength of these positive results from the...